Global Biosimilar Testing and Development Services Market Growth (Status and Outlook) 2023-2029

Global Biosimilar Testing and Development Services Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Biosimilar Testing and Development Services Industry Forecast” looks at past sales and reviews total world Biosimilar Testing and Development Services sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar Testing and Development Services sales for 2023 through 2029. With Biosimilar Testing and Development Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Testing and Development Services industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Testing and Development Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Testing and Development Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Testing and Development Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Testing and Development Services and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Testing and Development Services.

The global Biosimilar Testing and Development Services market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The global biosimilar testing and development services is segmented on the basis of clinical assays, comparability testing, and region. On the basis of clinical assays, it is divided into PK assay, tiered immunogenicity testing, and NAb assays. On the basis of comparability testing, it is classified into effector binding, ELISA, kinetic binding assays, and ADCC & CDC cell-based assays.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Testing and Development Services market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Effector Binding
ELISA
Kinetic Binding Assays
ADCC & CDC Cell-Based Assays

Segmentation by application
PK assay
Tiered Immunogenicity testing
NAb assays

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eurofins Scientific
SGS
Charles River Laboratories
Pharmaceutical Product Development
Exova
Source BioScience
Intertek Group
Medistri
Pace Analytical Services
Sigma-Aldrich

Please note: The report will take approximately 2 business days to prepare and deliver.